O'Connor Padraig Andrew 4

4 · BOSTON SCIENTIFIC CORP · Filed Feb 17, 2026

AI-generated summary of this filing

Updated Feb 18, 2026

Boston Scientific (BSX) EVP Padraig O'Connor Exercises Options, Withholds Shares

What Happened

Padraig Andrew O'Connor, EVP, Global Operations of Boston Scientific, reported derivative activity and awards on Feb 12, 2026. The Form 4 shows an exercise/conversion of 1,058 derivative shares (code M) and a tax/withholding disposition of 457 shares at $74.12 each, totaling $33,873 (code F). The filing also reports awards/grants of 5,059 and 11,939 derivative units (code A), each reported at $0 per share.

Key Details

Transaction date: February 12, 2026; Form 4 filed February 17, 2026 (within typical two business-day reporting window given the Feb 16 holiday).
Exercise/conversion: 1,058 derivative shares (code M) reported at $0 per share.
Tax withholding: 457 shares withheld (code F) at $74.12 = $33,873 to satisfy tax obligations.
Awards/grants: 5,059 and 11,939 derivative units reported as acquired (code A) at $0 per share.
Footnotes:
- F1: Reported restricted stock units (RSUs) represent a commitment to issue one share per unit.
- F2: The 5,059 award vests in four equal annual installments beginning Feb 12, 2025.
- F3: The 11,939 award vests in four equal annual installments beginning Feb 12, 2027.
- F4: A grant of options (vesting in four equal annual installments beginning Feb 12, 2027) is referenced.
Shares owned after the transaction are not provided in the information supplied in this summary.

Context

The 457-share disposition is a tax withholding event (common when RSUs vest or options are exercised) rather than an open-market sale — the shares were retained by the issuer to cover taxes, not necessarily sold on the market by the insider.
The filings are mostly awards and derivative conversions (not new open-market purchases), so they reflect compensation-related equity activity rather than an outright buy/sell decision by the insider.
No indication in the supplied data that this is a 10% owner transaction or a 10b5-1 plan; the activity appears to be routine compensation vesting/exercise and associated tax withholding.

Form 4

Period: 2026-02-12

EVP, Global Operations

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-12+1,058→ 4,943 total
Tax Payment
Common Stock
2026-02-12$74.12/sh−457$33,873→ 4,486 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-02-12−1,058→ 2,116 total
Exp: 2028-02-12→ Common Stock (1,058 underlying)
Award
Restricted Stock Units
[F1][F3]
2026-02-12+5,059→ 5,059 total
Exp: 2030-02-12→ Common Stock (5,059 underlying)
Award
Stock Option (Right to Buy)
[F4]
2026-02-12+11,939→ 11,939 total
Exercise: $74.12Exp: 2036-02-12→ Common Stock (11,939 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
[F2]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.
[F3]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
[F4]Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.

Signature

/s/ Susan Thompson, Attorney-in-Fact|2026-02-17

1 file